TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01524783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Participants were treated with everolimus 10 mg (two 5 mg tablets) once daily orally taken

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were treated with two tablets of matching placebo once daily orally taken.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best suportive care (BSC)
Description: Best supportive care includes all care provided to participants deemed necessary by the treating physician, such as but not restricted to anti-diarrheals and analgesics. The optimal care of the patient is based on the treating physician's best medical judgment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best suportive care (BSC)
Description: Best supportive care includes all care provided to participants deemed necessary by the treating physician, such as but not restricted to anti-diarrheals and analgesics. The optimal care of the patient is based on the treating physician's best medical judgment.
Study: NCT02333721

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy including No. 10
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: D2 lymphadenectomy excluding No. 10
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
Study: NCT01632904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be orally self-administered at a starting dose of 10 mg (two 5 mg tablets) twice a day. Dose increases of 5 mg (1 tablet) in twice-daily increments are permitted after 4 weeks and again after 8 weeks of therapy for subjects who meet prespecified criteria for inadequate efficacy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea (HU)
Description: Hydroxyurea (500 mg capsules) will be orally self-administered at the dose that the subject was receiving previously. The dose may be increased after 4 weeks and again after 8 weeks of therapy to optimize efficacy for subjects meeting prespecified criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HU-placebo
Description: All placebo will be self-administered, and dosing will be the same as with the blinded dose.~When adjustments are made to the ruxolitinib dose, the dose of HU-placebo will be adjusted concurrently.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib-placebo
Description: All placebo will be self-administered, and dosing will be the same as with the blinded dose.~When adjustments are made to the HU dose, the dose of ruxolitinib-placebo will be adjusted concurrently.
Study: NCT04457375

Intervention type: DIAGNOSTIC_TEST
Intervention: TDC
Description: measurements
Study: NCT01552915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate
Description: Daily oral dosing in the AM of optimized dose, ranging from 30- 70 mg. 5 week dose optimization, 3 week dose maintenance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate Hydrochloride
Description: Daily oral dosing in the AM of optimized dose, ranging from 18-72 mg. 5 week dose optimization, 3 week dose maintenance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral dosing in the AM for 8 weeks
Study: NCT03547362

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Casein
Description: See arm description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy protein blend 1
Description: See arm description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: See arm description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy protein blend 2
Description: See arm description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy protein blend 3
Description: See arm description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy protein blend 4
Description: See arm description
Study: NCT01546168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: esophageal deviation with IDE device
Description: esophageal deviation during AF ablation
Study: NCT03978247

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NASHMIR
Description: An additional blood sample will be taken upstream of the surgical procedure and a liver biopsy will be performed in all included patients. The two results obtained by the spectroscopic test and by means of the biopsy will then be compared to determine the diagnostic performance of the developped test (NASHMIR test).
Study: NCT00175032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole and naproxen and aspirin
Description: Lansoprazole 30 mg, capsules, orally once daily; Naproxen 500 mg, capsules, orally, twice daily; and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib and aspirin
Description: Celecoxib 200 mg, capsules, orally once daily and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.
Study: NCT01756105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin: from 500 mg 2 time per day to 2500 mg per day; with increment of 500 mg every 5 days until abstention of

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapid acting analog insulin Intermediate acting NPH Insulin
Description: Insulin therapy:If post meal (2 hours after meal) glycaemia is \> to 120 mg/dl introduce Insulin rapid acting analog (Humalog\*, Novorapid\*) before the meal concerned and according to the weight. If weight is \< 80 kg: breakfast 5U, lunch time 3U, and dinner 4U. If weight is \> 80 kg :breakast 6U, lunch time 4U, dinner 5U.If post meal glycaemia stay over 120 mg/dl but lower than130 mg/dl: do 1 U more.If post meal glycaemia stay over 140 mg/dl : do 2 UI moreIf fasting glycaemia is over 95 mg/dl : introduce NPH Insulin (Umuline NPH\*, insulatard\*) before sleeping : 5U if weight is \< 80 kg - 6U if weight is \> 80 kgIf fasting glycaemia stay over 95 mg/dl increase NPH Insulin for 1 U and for 2 U if fasting glycaemia is over 110 mg/dl.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapid acting analog insulin Intermediate acting NPH Insulin
Description: Insulin therapy:If post meal (2 hours after meal) glycaemia is \> to 120 mg/dl introduce Insulin rapid acting analog (Humalog\*, Novorapid\*) before the meal concerned and according to the weight. If weight is \< 80 kg: breakfast 5U, lunch time 3U, and dinner 4U. If weight is \> 80 kg :breakast 6U, lunch time 4U, dinner 5U.If post meal glycaemia stay over 120 mg/dl but lower than130 mg/dl: do 1 U more.If post meal glycaemia stay over 140 mg/dl : do 2 UI moreIf fasting glycaemia is over 95 mg/dl : introduce NPH Insulin (Umuline NPH\*, insulatard\*) before sleeping : 5U if weight is \< 80 kg - 6U if weight is \> 80 kgIf fasting glycaemia stay over 95 mg/dl increase NPH Insulin for 1 U and for 2 U if fasting glycaemia is over 110 mg/dl.
Study: NCT03480698

Intervention type: DRUG
Intervention: Cerebrolysin
Description: Dosage, frequency, duration and mode of administration of Cerebrolysin follow the local hospital practice in accordance with the terms of the local marketing authorization and is not amended or influenced by the study. Prescribed Cerebrolysin will be used as solution for injection/concentrate for solution for infusion.
Study: NCT00962091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib OS Alisertib PIC Alisertib PIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib OS Alisertib PIC Alisertib PIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib OS Alisertib PIC Alisertib PIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib OS Alisertib PIC Alisertib PIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib OS Alisertib PIC Alisertib PIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib OS Alisertib PIC Alisertib PIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib OS Alisertib PIC Alisertib PIC
Study: NCT03491631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR9146+SHR-1210
Description: SHR9146: Initial dose of 100mg BID with escalation planned to 600mg BID; SHR-1210: 200mg Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR9146+SHR-1210+Apatinib
Description: SHR9146: Initial dose of 100mg BID with escalation planned to 600mg BID; SHR-1210: 200mg Q2W Apatinib:250mg QD
Study: NCT02034396

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Draw
Description: One blood draw at enrollment
Study: NCT01001598

Intervention type: DRUG
Group type: OTHER
Intervention: danazol
Description: Dosage is done according to weight; capsules are 50, 100, 200 mg
Study: NCT00711828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
Study: NCT01759316

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: heliox
Description: heliox or oxygen is used in the two groups respectively

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: heliox
Description: heliox or oxygen is used in the two groups respectively
Study: NCT02253771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shockwave therapy
Description: Shockwave therapy with 2000 impulses/treatment at 12 Hz; 8 treatment over 4 weeks, twice a week

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo shockwave therapy
Description: sham shockwave therapy by an identically looking device without any function
Study: NCT03243344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgiflo
Description: using device during the endonasal surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Floseal
Description: using device during the endonasal surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Algosteril
Description: using device during the endonasal surgery.
Study: NCT01979471

Intervention type: OTHER
Group type: OTHER
Intervention: Advanced Care
Description: The pharmacist will complete a Comprehensive Annual Care Plan (CACP) or Standard Medication Management Assessment (SMMA), which will include:~* Patient assessment~* Laboratory assessment of HbA1c and lipids~* Individual assessment of CVD risk and education about this risk~  * Calculation of cardiovascular risk will be facilitated by an online tool~ * Discussion of CVD risk with the patient using the interactive online tool which explains his/her individual cardiovascular risk and targets for intervention and providing the patient with education on cardiovascular risk factors and healthy lifestyle options~* Treatment recommendations, Prescription adaptation(s), and/or prescribe where necessary to meet lipid, blood pressure and glycemic control targets and smoking cessation.~* Regular communication with the patient's family physician after each contact with the patient~* Regular follow-up with all patients a minimum of every 3-4 weeks for 3 months.
Study: NCT00150124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTZ+LT4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methimazole
Study: NCT01772849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors Continued individualized education at the hospital school or at home that parallels/copies the educational curriculum in the child regular school At two weks intervals joined education, physical (separate study) and social activity days at the hospital with together with one of the ambassadors
Study: NCT02056106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antidepressant therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antidepressant therapy
Study: NCT01070836

Intervention type: DRUG
Intervention: natalizumab
Description: Administered as specified in the treatment arm
Study: NCT02416648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician Client Centered (CCC) Counseling
Description: Counseling sessions were interactive allowing for listening, questions and answers. They were cultural sensitive and also consider issues related to gender and age. Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.~Clinicians evaluated patients' readiness to change risky or maintain safer behaviors. They also assisted the patient to negotiate an individually tailored behavior change or maintenance plan of action.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician Client Centered (CCC) Counseling
Description: Counseling sessions were interactive allowing for listening, questions and answers. They were cultural sensitive and also consider issues related to gender and age. Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.~Clinicians evaluated patients' readiness to change risky or maintain safer behaviors. They also assisted the patient to negotiate an individually tailored behavior change or maintenance plan of action.
Study: NCT01881880

Intervention type: DEVICE
Group type: OTHER
Intervention: Bilateral mammography with Tomosynthesis
Description: no intervention pre specified to be administered to participants
Study: NCT02294175

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Larval Debridement Therapy
Description: small sterile mesh bags containing live maggots placed into an open chronic wound to remove necrotic tissue and bacterial biofilm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bedside Sharp Debridement
Description: The use of a sharp clinical instrument (currette, scalpel, scissors, forceps) by a qualified clinician to remove necrotic tissue and bacterial biofilm from an open chronic wound
Study: NCT04216446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Health Intervention
Description: A mobile based application will be developed that will function on android as well as the iPhone operating system. The application will be provided to eligible pregnant women randomized to the intervention group. The dietary, supplement use and physical activity coaching will be provided over the period of 6 months through the application.
Study: NCT02945397

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group-based activity
Description: Regular follow-up from welfare authority as well as a 3 month group activity with weekly gatherings, focusing on coping, goal-setting and relevant information regarding available public services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual activity
Description: Regular follow-up from welfare authority as well as a 3 month membership card at a given gym.
Study: NCT02826265

Intervention type: DEVICE
Intervention: multiple breath washout test (MBW)

Intervention type: DEVICE
Intervention: impulse oscillometry (IOS)

Intervention type: DEVICE
Intervention: body plethysmography (BP)

Intervention type: DEVICE
Intervention: quantitative computed tomography (qCT)
Description: ultra-low-dose qCT
Study: NCT01877382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan
Description: DS-3032b will be administered as an oral capsule. It will be supplied in 5, 20, 80, and/or 200 mg capsules individually packaged in desiccant-embedded aluminum blisters.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan
Description: Milademetan will be administered as a single oral capsule or as a combination of multiple oral capsules containing 5, 20, 80, and/or 200 mg. An alternate combination of 30 and/or 100 mg capsules of milademetan may be utilized.
Study: NCT02262000

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image Guided Stereotactic Ablative Radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image Guided Stereotactic Ablative Radiotherapy
Study: NCT02402634

Intervention type: OTHER
Intervention: Mechanical ventilatory lung care
Study: NCT04586218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer guided vasopressor infusion
Description: automated titration of vasopressor infusion to maintain a mean arterial pressure \> 65mmHg

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Manual control of vasopressor infusion
Description: manual adjustments of noradrenaline infusion
Study: NCT00663897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lansoprazole
Description: lansoprazole, 30 mg, once daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mosapride
Description: mosapride, 5 mg, thrice daily for 14 days
Study: NCT00326781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicoderm Transdermal Patch
Description: The dosing schedule is as follows: 4 weeks of 21mg per 24 hours, 2 weeks of 14mg per 24 hours, and 2 weeks of 7mg per 24 hours. Treatment lasted 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Nasal Spray
Description: 8 weeks of self-administered nicotine nasal spray at 40 recommended doses per day, tapering by 1/3 for the last 4 weeks. Nasal spray dosing was 0.5 mg spray per nostril (1 mg) for a maximum of 5 doses per hour and 40 doses per day. This dosing schedule is based on the average nicotine intake per cigarette of 1 mg per cigarette. Treatment lasted 8 weeks.
Study: NCT03990935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ginger and rosemary gel
Description: First the participant will be asked to brush his/her teeth thoroughly with 1450 ppm fluoride toothpaste (Colgate total healthy clean toothpaste). Then an application of a thin ribbon of this gel to the teeth using a brush. The medication will be left for at least 1 minute. The participant will be asked to spit out the medication after use and not to swallow it. Also the participant will be asked not to rinse his/her mouth, eat, or drink for at least 30 minutes after use to get the best results.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ginger and rosemary gel
Description: First the participant will be asked to brush his/her teeth thoroughly with 1450 ppm fluoride toothpaste (Colgate total healthy clean toothpaste). Then an application of a thin ribbon of this gel to the teeth using a brush. The medication will be left for at least 1 minute. The participant will be asked to spit out the medication after use and not to swallow it. Also the participant will be asked not to rinse his/her mouth, eat, or drink for at least 30 minutes after use to get the best results.
Study: NCT03295552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: decitabine 7mg/m2, d1-d5, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC = 6, d6, q3w
Study: NCT01091545

Intervention type: RADIATION
Group type: OTHER
Intervention: DBT and FFDM
Description: Women in the study will once undergo both standard FFDM screening (2-views) and DBT (1 view, MLO). This will result in a doubled radiation dose compared to only 2-view FFDM, which is the standard procedure for women in the screening program.
Study: NCT00900731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Description: Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium 18 μg
Description: Tiotropium 18 μg was provided in powder filled capsules with the manufacturer's proprietary inhalation device (HandiHaler®).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to tiotropium
Description: Placebo to tiotropium was provided in powder filled capsules with the manufacturer's proprietary inhalation device (HandiHaler®).
Study: NCT01763723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPL-home use device
Description: A light based home use device for hair removal
Study: NCT03944733

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron
Description: 65 mg of iron (ferrous sulfate)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Gelatin
Description: 600 mg gelatin
Study: NCT01914159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany)
Description: Monthly intravitreal injections
Study: NCT04375904

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image-Guided Stereotactic Ablative Radiotherapy (IG-SABR)
Description: Image-Guided Stereotactic Ablative Radiotherapy (IG-SABR) delivered in 8 fractions of 7.5 Gy. OAR constraints must be respected but a minimum dose coverage to 95% of the PTV will be allowed down to 75% and a minimum dose to 99% of the GTV allowed at 75%. Respiratory monitoring/active respiratory management will be used. Plans will be created and delivered using photon beams with energies between 6-10 MV.